Organon completes global MIUDELLA copper IUD licensing deal with Sebela

Organon & Co.

Organon & Co.

OGN

0.00
  • Organon completed a global licensing deal with Sebela for exclusive rights to MIUDELLA, a hormone-free copper IUD.
  • MIUDELLA won FDA clearance on Feb. 24, 2025; indicated to prevent pregnancy for up to three years; 99% effective.
  • Commercial launch targeted for late 2026; US distribution restricted to a REMS program requiring provider training.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260622937193) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.